je.st
news
Tag: inhibitor
Kao Patents Melanin Decomposition Inhibitor
2021-04-29 21:20:50| Happi Breaking News
External preparation contains proguanil.
Tags: patents
inhibitor
kao
decomposition
Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine
2016-11-02 21:30:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Results of First Phase 3 Trial Anticipated in Late 2017 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat, an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), for the potential treatment of Alzheimers disease (AD). Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orIan McConnell, 908-740-1921orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: research
development
science
early
Researchers improve aluminum-air battery performance by using flax straw extract as corrosion inhibitor
2016-07-28 18:55:59| Green Car Congress
Tags: performance
improve
battery
researchers
Results of Phase 2 Study of Mercks Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
2016-06-20 18:30:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Pivotal Phase 3 Studies Ongoing in Treatment of Serious Bacterial Infections KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the companys investigational beta-lactamase inhibitor, in combination with imipenem/cilastatin (an approved carbapenem antibiotic), in patients with complicated urinary tract infections, met its primary endpoint. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558orRobert Consalvo, (908) 295-0928orInvestor:Teri Loxam, (908) 740-1986orAmy Klug, (908) 740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
study
presented
combination
Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes
2016-06-11 17:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. & NEW YORK Ongoing CV Outcomes Trial of Ertugliflozin Expanded to Test for Superiority in CV Risk Reduction KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints. The study results showed statistically significant reductions in A1C (a measure of average blood glucose) for both ertugliflozin doses tested (5 mg and 15 mg daily). Language: English Contact: Merck Media Contacts:Doris Li, 908-246-5701orKristen Drake, 908-334-4688orMerck Investor Contact:Justin Holko, 908-740-1879orPfizer Media Contact:Steve Danehy, 212-733-1538orPfizer Investor Contact:Ryan Crowe, 212-733-8160 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: PFE Exchange: NYSE read more